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CD4+ and B Lymphocyte Expression Quantitative Traits at
Rheumatoid Arthritis Risk Loci in Patients With
Untreated Early Arthritis
Implications for Causal Gene Identification
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Amy E. Anderson,1 Alexander D. Clark,1 Julie Diboll,1 Dennis W. Lendrem,1
Louise N. Reynard,1 Heather J. Cordell,3 Stephen Eyre,2 John D. Isaacs,1
Anne Barton,2 and Arthur G. Pratt1
Objective. Rheumatoid arthritis (RA) is a geneti-
cally complex disease of immune dysregulation. This
study sought to gain further insight into the genetic
risk mechanisms of RA by conducting an expression
quantitative trait locus (eQTL) analysis of confirmed
genetic risk loci in CD4+ T cells and B cells from care-
fully phenotyped patients with early arthritis who were
naive to therapeutic immunomodulation.
Methods. RNA and DNA were isolated from
purified B and/or CD4+ T cells obtained from the
peripheral blood of 344 patients with early arthritis.
Genotyping and global gene expression measurements
were carried out using Illumina BeadChip microarrays.
Variants in linkage disequilibrium (LD) with non-HLA
RA single-nucleotide polymorphisms (defined as r2 ≥
0.8) were analyzed, seeking evidence of cis- or trans-
eQTLs according to whether the associated probes were
or were not within 4 Mb of these LD blocks.
Results. Genes subject to cis-eQTL effects that
were common to both CD4+ and B lymphocytes at RA
risk loci were FADS1, FADS2, BLK, FCRL3, ORMDL3,
PPIL3, and GSDMB. In contrast, those acting on
METTL21B, JAZF1, IKZF3, and PADI4 were unique to
CD4+ lymphocytes, with the latter candidate risk gene
being identified for the first time in this cell subset. B
lymphocyte–specific eQTLs for SYNGR1 and CD83 were
also found. At the 8p23 BLK–FAM167A locus, adjacent
genes were subject to eQTLs whose activity differed
markedly between cell types; in particular, the FAM167A
effect displayed striking B lymphocyte specificity. No
trans-eQTLs approached experiment-wide significance,
and linear modeling did not identify a significant influ-
ence of biologic covariates on cis-eQTL effect sizes.
Conclusion. These findings further refine the
understanding of candidate causal genes in RA patho-
genesis, thus providing an important platform from
which downstream functional studies, directed toward
particular cell types, may be prioritized.
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Rheumatoid arthritis (RA) is a complex genetic
disease in which immune tolerance becomes impaired,
and an unchecked inflammatory response leads to
chronic pain and damage to the synovial joints (1).
Genetic variation at the HLA–DRB1, HLA–DPB, and
HLA–B loci accounts for a large proportion of the
known RA risk (2), with implications for antigen pre-
sentation to T lymphocytes (3,4). Outside of the HLA
region, accumulating data now highlight an overlap
between the 101 confirmed RA risk loci and cell-spe-
cific enhancer elements, which is maximal in CD4+
lymphocytes followed by B lymphocytes (5–8). Such
molecular insights support a pivotal role for both
CD4+ T cell and B cell lineages in the pathogenesis of
RA (9–11). Mapping cellular mechanisms of genetic
risk in the disease is far from straightforward, however,
because lead single-nucleotide polymorphisms (SNPs)
at associated loci are typically noncoding and inter-
genic, tagging linkage disequilibrium (LD) blocks that
contain multiple genes (7,12).
To prioritize causal genes, one solution is to
explore associations between genetic variants and down-
stream molecular quantitative traits, the most proximal
of which is gene expression. Thus, with respect to a puta-
tive susceptibility gene, colocalization of an expression
quantitative trait locus (eQTL) with a disease risk vari-
ant implicates the gene as a candidate for disease causa-
tion (13). Data from eQTL studies in healthy human
subjects have indeed informed algorithms for prioritiza-
tion of candidate genes in RA (7). Importantly, however,
it is now clear that the transcriptional consequences of
genetic variation can manifest as cell type specificity,
with potentially profound implications for disease patho-
genesis (14,15). For example, it has been observed that
only 22% of cis-eQTLs are consistently identified in dif-
ferent circulating cell subsets from healthy donors;
eQTLs present in a specific cell type may not be detect-
able in another cell type or in whole blood—and vice
versa. Moreover, a number of eQTLs can be detected
only under specific conditions of cell stimulation
(14,16,17). This suggests that the contribution of eQTL
data to inferred causality among candidate genes for a
given disease must increasingly be understood at a cellu-
lar level and within a relevant biologic context (18).
The suggestion that the effect size of a risk vari-
ant’s influence on gene expression may depend on the
environmental parameters to which cells are exposed has
potentially important implications for understanding the
complexities of disease induction. In RA, for example,
the unmasking of eQTL effects in relevant cell popula-
tions during a transient systemic trigger might plausibly
be sufficient to break immune tolerance, permitting a
transition to persistent joint inflammation. Against this
backdrop, we set out to reassess the biologic landscape of
candidate susceptibility genes in RA by mapping cis- and
trans-eQTLs at 101 established RA risk loci in circulating
CD4+ and B lymphocyte subsets sampled from a cohort
of untreated patients with early arthritis. In so doing, we
sought insight into potential common and/or cell-specific
mechanisms of genetic risk in a highly relevant biologic
context, free from the confounding influences of in vivo
immune modulation or ex vivo manipulation.
PATIENTS AND METHODS
Patients. Patients with early arthritis (all of self-
reported white ethnicity) who were attending the Newcastle
Early Arthritis Cohort (NEAC) clinic in the UK were
recruited into the study, and peripheral blood samples were
obtained prior to the commencement of immunomodulatory
therapy; individuals who were exposed to steroid treatment
during the 3 months prior to recruitment or those whose eth-
nic origin, determined by genotype, was not of white North-
ern European descent were excluded from the analyses. This
resulted in 71 patients being recruited between January 2008
and December 2009, and a further 273 during 2012 and 2013;
the NEAC cohort has been described in detail elsewhere (19–
22). Initial diagnoses were validated at follow-up visits over a
median period of 20 months (range 13–25 months; duration
of follow-up >1 year in all cases), as described previously
(19,21). All patients gave their written, informed consent for
inclusion into the study, which was approved by the local
Regional Ethics Committee.
Measurements of gene expression, data curation, and
quality control. Whole peripheral blood was stored at room
temperature for ≤4 hours before processing. CD4+ lympho-
cytes were isolated from the peripheral blood by positive
selection, as previously described (21), yielding a median cell
purity of 98.9%. To obtain B lymphocytes, peripheral blood
mononuclear cells were first isolated by density centrifugation
using the Lymphoprep protocol (Axis-Shield Diagnostics), and
then subjected to positive selection using anti-CD19 magnetic
microbeads (Miltenyi Biotec). The median cell purity was
96.4%, as determined by flow cytometry (see Supplementary
Figure 1, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.40393/abstract).
RNA was immediately extracted from total CD4+ T
cells or B lymphocytes using an RNeasy Mini kit (prior to
2012) or AllPrep DNA/RNA Mini kit (both from Qiagen),
and then subject to quality control using an Agilent 2100 Bio-
analyzer (Agilent). The median RNA integrity number in the
samples analyzed was 9.4. Complementary RNA generated
from 250 ng total RNA (Illumina TotalPrep RNA Amplifica-
tion kit) was hybridized to either an Illumina Whole Genome
6 version 3 (using CD4+ lymphocyte samples obtained prior
to 2012) or a 12HT BeadChip (using CD4+ T cell samples
obtained in or after 2012, and all B cell samples) (both from
Illumina). The analysis was limited to probes determined
to be common to both array platforms, based on unique
capture sequence identifiers. Those liable to cross-hybridization
according to probe-sequence BLATanalysis were then excluded.
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Following normalization (robust spline normalization)
and variance stability transformation (23,24), batch correction
of the data from CD4+ cells by linear modeling (25), and
merging of the component data sets (26), principal compo-
nents analysis was carried out to confirm correction for tech-
nical bias (see Supplementary Figure 2, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40393/abstract). The raw and processed
expression data used in this study are available in the Gene
Expression Omnibus database (accession nos. GSE20098,
GSE80513, or GSE100648; http://www.ncbi.nlm.nih.gov/geo) (a
complete list of unique identifiers is provided in Supplementary
Table 1, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.40393/abstract).
Genotyping. Genomic DNA was isolated from the
peripheral blood of all patients, either from the whole blood
using the Wizard genomic DNA purification kit (Promega) (for
samples obtained prior to 2012) or from isolated lymphocytes
in parallel with RNA extraction (AllPrep DNA/RNA Mini kit;
Qiagen). Genotyping was carried out using an Illumina Human
CoreExome-24 version 1-0 array, following the manufacturer’s
protocol. Samples and SNPs with a call rate of <98% were
excluded. In addition, SNPs with a minor allele frequency of
<0.01 or an Illumina GenomeStudio cluster separation of <0.4
were excluded from further analysis. Data were pre-phased
using SHAPEIT2 and imputed to the 1000 Genomes Phase 1,
version 3, reference panel using IMPUTE2. Imputed SNPs with
INFO scores of <0.8 were excluded.
Analysis of eQTLs and covariates. Analysis of eQTLs
was limited to loci defined by the 101 lead disease-associated
variants confirmed to be present in Caucasians, as previously
described by Okada et al (7). For this analysis, linear models
were fitted and residual analysis was performed to verify
model assumptions using the R package; Pearson’s R2 statis-
tics and associated P values were derived. Due to abundant
cross-hybridization of the expression probes and the con-
founding effect of copy numbers within the HLA region, we
limited our analysis to non-HLA variants. Permutation testing
(10,000 permutation replicates) was carried out to derive
experiment-wide P values equivalent to a predetermined a
value of 5%; a more relaxed (though nonetheless robust) sig-
nificance threshold was also defined at an a value of 10%.
This method, utilized to correct for multiple testing, proved
more stringent than the standard Benjamini-Hochberg
method, which was also applied for comparison. A general
linear model incorporating other potential biologic and clini-
cal parameters, including age, sex, C-reactive protein (CRP)
level, and swollen joint count, permitted evaluation of the
robustness of the eQTLs in relation to inflammation markers
and other potential covariates.
Comparisons with published data sets. Published
eQTL data sets were identified using PubMed literature
searches. Results were cross-checked and validated with refer-
ence to the GTEx Portal database (available at http://gtexportal.
org) (27).
RESULTS
Mapping of eQTLs at RA risk loci in lymphocytes
of treatment-naive patients with early arthritis. Expres-
sion data from primary peripheral blood lymphocytes
were available for a total of 344 genotyped patients with
early arthritis; available data on CD4+ lymphocytes were
Table 1. Characteristics of the patients with early arthritis*
RA
(n = 124)
Non-RA
inflammatory arthritis
(n = 113)
Noninflammatory arthritis
(n = 107) P†
Age, years 59 (48–73) 51 (39–63) 52 (44–57) <0.001
Sex, % female 69 61 81 <0.001
Duration of symptoms, weeks 12 (8–27) 12 (6–25) 24 (8 to >52) 0.03
CRP, gm/liter 11 (5–26) 8 (5–19) <5 (<5–8) <0.001
ESR, mm/minute 26 (12–49) 19 (7–34) 8 (4–20) <0.001
TJC 6 (3–12) 2 (1–6) 3 (0–8) 0.001
SJC 2 (1–6) 1 (0–3) 0 (0–0) <0.001
DAS28 4.68 (3.5–5.5) NA NA NA
RF positive, % 57 7 14 <0.001
ACPA positive, % 48 2 1 <0.001
Non-RA diagnosis, %
Osteoarthritis – – 55 –
Other, noninflammatory arthritis – – 45 –
Spondyloarthropathy (PsA, AS, EA) – 68 – –
Crystal arthropathy – 9 – –
Other, inflammatory arthritis – 20 – –
Undifferentiated arthritis – 3 – –
* Patients with early arthritis are stratified by diagnostic category, including non–rheumatoid arthritis (RA) subclassifica-
tions. Except where indicated otherwise, values are the median (interquartile range). CRP = C-reactive protein; ESR =
erythrocyte sedimentation rate; TJC = tender joint count (of 28 joints); SJC = swollen joint count (of 28 joints); DAS28 =
Disease Activity Score in 28 joints; NA = not applicable; RF = rheumatoid factor; ACPA = anti–citrullinated peptide
autoantibody; PsA = psoriatic arthritis; AS = ankylosing spondylitis; EA = enteropathic arthritis.
† P values were based on Kruskal-Wallis nonparametric analysis of variance for continuous variables, and chi-square test
for dichotomous variables.
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limited to 249 of the patients, data on B lymphocytes
were available for 242 of the patients, and paired data
were available for 147 of the patients. The baseline clini-
cal characteristics and diagnoses of all patients are sum-
marized in Table 1. After quality control procedures were
applied, a total of 1,227 genotyped variants in LD
(defined as r2 ≥ 0.8) with lead RA-associated SNPs were
considered. Filtered expression probes whose start sites
mapped to within 4 Mb of LD blocks (as defined in
Patients and Methods) were initially measured to identify
cis-acting eQTLs. In a secondary analysis of trans-eQTLs,
those with start sites >4 Mb from the same LD blocks
were evaluated in a similar manner.
Permutation testing was carried out using 10,000
permutation replicates for each analysis in each lympho-
cyte subset. This allowed us to account for multiple test-
ing, in which the total number of tests for each cell
type corresponded to the number of unique SNP–gene
pairs in the analyses of cis- or trans-acting eQTLs across
the prespecified loci, after data processing and quality
control had been performed. The maximum value of the
test statistic (minimum nominal P value) across the total
number of tests in each permutation replicate was
recorded, and significance thresholds exceeding 5%
or 10% in each permutation replicate were determined.
This procedure resulted in experiment-wide P value
thresholds (a = 5% or a = 10%) that were used to define
evidence of eQTLs in each cell type, as summarized in
Figure 1 (for cis-eQTL analyses) and in Supplementary
Figure 3 (for trans-eQTL analyses; available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40393/abstract).
In total, 213 cis-acting significant SNP–transcript
associations were identified in CD4+ lymphocytes (a =
5%), corresponding to 10 unique genes at 7 established
RA risk loci; 194 cis-eQTLs were similarly identified in B
lymphocytes (a = 5%), also corresponding to 10 unique
genes at 7 loci. The cis-eQTL effects for FADS1, FADS2,
FCRL3, BLK, ORMDL3, GSDMB, and PPIL3 were
robust in both CD4+ and B lymphocytes at RA risk loci.
The eQTLs acting on 3 genes (METTL21B, IKZF3, and
JAZF1) were unique to CD4+ T lymphocytes in this pop-
ulation, with PADI4 also subject to a convincing effect
exclusively in this cell type despite falling marginally
Figure 1. Determination of experiment-wide significance of cis-acting expression quantitative trait loci (cis-eQTLs) in CD4+ T lymphocytes (A)
and CD19+ B lymphocytes (B). Top, Histograms summarize the data from 10,000 permutation replicates, each derived from the indicated number
of single-nucleotide polymorphisms (SNPs) and expression probes, and the final number of included tests. P values at the a = 5% and a = 10%
thresholds are shown. Bottom, QQ plots depict expected P value distributions under the null hypothesis (red line) versus observed distributions.
Analogous plots for analyses of trans-eQTLs are shown in Supplementary Figure 3 (available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40393/abstract).
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short of the a = 10% threshold by permutation analysis;
the latter gene encodes a peptidylarginine deiminase
enzyme, and therefore is of interest in the pathogenesis
of RA (28).
At the 8p23 locus, FAM167A was, in contrast to
the neighboring BLK gene, shown to be subject to cis
regulation only in B lymphocytes, and SYNGR1 and
CD83 eQTLs were also specific to this cell type. These
data are summarized in Tables 2 and 3 and depicted
as Manhattan plots in Figure 2. No trans-eQTLs
achieved experiment-wide significance thresholds, either
in CD4+ T lymphocytes or in B lymphocytes.
Representative examples of eQTL plots are
depicted in Figure 3, and a comprehensive list of all
SNP–probe associations that remained significant after
Benjamini-Hochberg correction for multiple testing is
provided in Supplementary Tables 2 and 3 (available on
the Arthritis & Rheumatology web site at http://onlinelib
rary.wiley.com/doi/10.1002/art.40393/abstract), in which
significance thresholds of a = 5% and a = 10% by per-
mutation testing are also indicated. Supplementary
Table 4 (http://onlinelibrary.wiley.com/doi/10.1002/art.
40393/abstract) summarizes this information, listing
all significant eQTL SNPs (and associated genes) in
Table 2. Summary of CD4+ T lymphocyte cis-eQTL genes*
Gene Lead eQTL SNP Locus Minor allele (MAF) P†
R2 in relation to RA
index SNP
Total no. of
significant SNPs
for probe‡
FADS1 rs968567 11q12 T (0.177) 1.06 9 10–27 1.0 3
BLK rs922483 8p23 T (0.426) 1.41 9 10–20 0.805 9
FADS2 rs968567 11q12 T (0.177) 2.40 9 10–20 1.0 3
METTL21B rs701006 12q13–q14 A (0.408) 3.65 9 10–19 1.0 3
FCRL3 rs2210913 1q23 C (0.457) 6.24 9 10–16 0.873 12
ORMDL3 rs4795397 17q12–q21 G (0.482) 1.07 9 10–14 0.959 66
PPIL3 rs6757776 2q33 G (0.103) 8.60 9 10–11 1.0 16
GSDMB rs4795397 17q12–q21 G (0.314) 6.92 9 10–10 0.969 88
IKZF3 rs1453559 17q12–q21 C (0.453) 2.52 9 10–9 0.801 23
JAZF1 rs4722758 7p15 G (0.195) 1.70 9 10–8 1.0 15
PADI4 rs2240339 1p36 T (0.418) 3.37 9 10–6§ 0.923 –
* Microarray probe targets are shown as Human Genome Organisation gene symbols. Lead expression quantitative trait locus
(eQTL) single-nucleotide polymorphisms (SNPs) and loci are also shown, along with their minor allele and minor allele frequency
(MAF). Rheumatoid arthritis (RA) index SNPs were those listed in the report by Okada et al (see ref. 7).
† The permuted significance thresholds of a = 5% and a = 10% equate to P = 6.48 9 107 and P = 1.96 9 10–6, respectively (see
Figure 1).
‡ Based on a threshold of a = 10%.
§ Data for the PADI4 eQTL fell marginally short of the a = 10% threshold.
Table 3. Summary of CD19+ B lymphocyte cis-eQTL genes*
Gene Lead eQTL SNP Locus Minor allele (MAF) P†
R2 with
RA index SNP
Total no. of
significant SNPs
for probe‡
FAM167A rs4840568 8p23 A (0.264) 2.48 9 10–80 0.817 9
FADS1 rs968567 11q12 T (0.177) 1.96 9 10–41 1.0 3
ORMDL3 rs9906951 17q12–q21 C (0.383) 2.29 9 10–35 0.881 66
FADS2 rs968567 11q12 T (0.177) 6.60 9 10–25 1.0 3
FCRL3 rs2210913 1q23 T (0.482) 3.09 9 10–22 0.839 12
GSDMB rs12936231 17q12–q21 G (0.434) 7.21 9 10–16 0.862 66
SYNGR1 rs909685 22q13 A (0.31) 3.66 9 10–14 1.0 5
BLK rs2618476 8p23 C (0.25) 3.02 9 10–13 0.958 9
PPIL3 rs2141331 2q33 T (0.097) 1.13 9 10–10 0.943 8
CD83 rs78242827 6p23 C (0.058) 2.72 9 10–8 1.0 20
* Microarray probe targets are shown as Human Genome Organisation gene symbols. Lead expression quantitative trait locus
(eQTL) single-nucleotide polymorphisms (SNPs) and loci are also shown, along with their minor allele and minor allele frequency
(MAF). Rheumatoid arthritis (RA) index SNPs were those listed in the report by Okada et al (see ref. 7).
† The permuted significance thresholds of a = 5% and a = 10% equate to P = 5.71 9 107 and 2.19 9 106, respectively (see
Figure 1).
‡ Based on a threshold of a = 10%.
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relation to the index SNPs reported by Okada et al (7).
Limiting any or all of the above analyses to samples
for which paired CD4+ and B lymphocytes were
available (n = 147) had no substantial effect on the
eQTL genes identified, although some associations
ceased to reach experiment-wide significance due to
Figure 2. Manhattan plots depict the 101 rheumatoid arthritis risk loci analyzed and P values for the significance of single-nucleotide polymor-
phism (SNP)–probe pairs (denoted by different-colored dots) among CD4+ T lymphocytes (top) and B lymphocytes (bottom) in patients with early
arthritis. Human Genome Organisation gene symbols for SNP–probe pairs, or groups thereof, that approached or reached experiment-wide signifi-
cance (at thresholds of a = 5% and a = 10% [horizontal lines]) are indicated, permitting comparison of expression quantitative trait loci between
cell types.
Figure 3. Representative examples of expression quantitative trait loci (eQTLs). Plots of normalized individual gene expression, along with their
Spearman’s rho statistics and P values for association, are shown for the lead eQTL single-nucleotide polymorphisms acting on FADS1 (A) and
PADI4 (B) in CD4+ T lymphocytes and FAM167A (C) in B lymphocytes.
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diminished power (see Supplementary Tables 5 and 6,
http://onlinelibrary.wiley.com/doi/10.1002/art.40393/
abstract).
Comparison of eQTLs with published data sets.
Our findings were considered in light of a number of
human eQTL studies for which significant SNP–probe
combinations are in the public domain. These included
analyses of cis-eQTLs in primary CD4+ and B lympho-
cytes. Murphy et al studied genome-wide expression in
positively selected whole CD4+ lymphocytes from 200
non-Hispanic white subjects, comprising young adults
with asthma and their first-degree relatives (29). Hu et al
examined paired expression limited to 270 genes in rest-
ing CD4+ lymphocytes and CD3/CD28-stimulated effec-
tor memory CD4+ lymphocytes from healthy donors;
genes were selected based on their proximity to 157
SNPs with known autoimmune disease associations (in-
cluding with RA) (30). Raj et al reported genome-wide
eQTL data in positively selected CD45RO (naive)
CD4+ lymphocytes from 200 healthy European Ameri-
cans (31), and a similar analysis, by Kasela et al, was con-
ducted in whole CD4+ (and CD8+) Tcells (32). Another
study, by Fairfax et al (14), demonstrated the presence
of eQTLs in primary B cells from 288 healthy Euro-
peans. Studies by Dixon and colleagues (33,34) pre-
sented cumulative data from Epstein-Barr virus–
transformed human B cells (lymphoblastoid cell lines),
and a large meta-analysis was conducted to compare
studies performed in the whole blood of predominantly
healthy volunteers (35). Finally, our data were consid-
ered in the context of the GTEx resource database (27).
Overlap between the genes subject to cis-eQTLs
in these studies compared with those identified in our
own study is illustrated in Supplementary Figure 4 (avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40393/abstract).
Reassuringly, all of the cis-eQTL genes identified in
patients with untreated early arthritis replicated the find-
ings reported in at least one of the comparator studies.
Strong independent validation of CD4+ lymphocyte–specif-
ic associations was provided with regard to 9 of the genes.
Among these, RA risk loci at 11q12 and at 17q12–21 were
each observed to harbor pairs of apparently coregulated
genes, FADS1/FADS2 and ORMDL3/GSDMB, respec-
tively. Moreover, at the 17q12–21 locus, IKZF3 was con-
firmed to be subject to a highly significant eQTL effect in
CD4+ lymphocytes (32). When a more lenient (but
nonetheless robust) method for multiple test correction
was employed, we highlighted, for the first time, an associ-
ation between PADI4 expression and genotype at the 1p36
locus specifically in CD4+ T cells, its having previously
been identified only in whole blood. Our findings with
respect to FAM167A, SYNGR1, and CD83 corroborate
those in the only other study of primary human B lympho-
cytes, by Fairfax et al (14), and although the same eQTLs
have been noted in mixed cell populations of whole blood
(35), no study (including our own) has yet replicated them
in CD4+ T lymphocytes.
Lack of significant impact of clinical covariates
on eQTLs. Because differential eQTL effect sizes have
been observed in paired CD4+ T cells from healthy
donors according to whether T cell receptor–mediated
stimulation of the cells was undertaken ex vivo prior to
RNA extraction (30), we hypothesized that certain clini-
cal covariates, and/or the activation status of circulating
CD4+ T cells, might have a similar influence in vivo.
The clinical parameters considered included age, sex,
CRP level, and erythrocyte sedimentation rate (as indi-
cators of the systemic acute-phase response), as well as
disease phenotype (RA versus non-RA). In the patient
subgroup for whom CD4+ lymphocyte expression data
were available, normalized transcript levels of CD25,
CD69, and interferon-c, as measured by microarray,
were also considered as surrogates of the CD4+ T cell
activation status. The incorporation of each of these
covariates, in turn, into linear models made no differ-
ence to the final eQTL list (as shown in Tables 2 and
3), and individual regression slopes were robust to their
inclusion (representative examples are depicted in Sup-
plementary Figure 5, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40393/abstract). Consistent with these
findings, lists of genes subject to cis-eQTL effects did not
vary substantially when patients with RA and those
with alternative diagnoses were considered indepen-
dently (results not shown). Thus, eQTLs were robust to
clinical and biologic covariates in our study, and no evi-
dence of early disease–specific eQTLs at RA risk loci was
found.
DISCUSSION
We present the first eQTL analysis of primary
lymphocytes from donors presenting with untreated,
suspected inflammatory arthritis—a context highly rele-
vant for the purpose of unravelling genetic risk mecha-
nisms in RA. Several important observations can be
made on the basis of our findings.
CD4+ and B lymphocytes in this setting exhibit
distinct but overlapping eQTLs at confirmed RA risk loci
(Tables 2 and 3). The specificity of an eQTL effect for
one cell type may simply be a reflection of the lack of
expression of a gene by a comparator cell, but probe-
level microarray data suggest that reported genes were
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expressed in both CD4+ and B lymphocytes in our study.
Therefore, the cell-specific effects that we observed for
METTL21B, IKZF3, JAZF1, and PADI4 (in CD4+ lym-
phocytes) and FAM167A, SYNGR1, and CD83 (in B lym-
phocytes) may indicate differential regulatory functions
of disease risk variants between lineages.
Strikingly, at the common BLK–FAM167A auto-
immune locus at 8p23, we found that 2 adjacent genes
were subject to eQTLs whose activity differed between
cell types: the FAM167A effect displayed robust B lym-
phocyte specificity and was absent in CD4+ lymphocytes,
whereas the BLK effect that was prominent in CD4+ T
lymphocytes was less prominent among B lymphocytes
(compare Table 2 and Table 3, and see Figure 2). The
most strongly associated SNPs differed between cell
types at this locus—a finding that was maintained among
patients for whom paired cell–specific data were
available (as shown in Supplementary Tables 5 and 6,
http://onlinelibrary.wiley.com/doi/10.1002/art.40393/abstract),
potentially signifying the presence of mechanistically
distinct regulatory variants in strong LD. Nonetheless, the
results of our study also contribute to an emerging picture
in which eQTLs can regulate the expression of more than
one gene at disease-associated loci, examples being found
at 11q12 and 17q12–21. This is consistent with the concept
that key genetic variants may act as “master regulators” of
gene expression.
Our findings provide an important platform from
which downstream functional studies may be directed
toward particular cell types. For example, elucidating the
relevance of the METTL21B gene product in CD4+ T
cell function would now seem a priority, given our find-
ings confirming a pronounced eQTL effect on this gene
in this cell type. Alternative causal candidate genes
known, to date, to be favored at the 12q13–q14 locus are
CDK4 and CYP27B1, based on their respective functions
in cell-cycle progression and vitamin D metabolism (7);
however, since neither of these genes were shown to be
subject to prominent eQTL effects, despite the growing
body of literature discussing their functions, it seems jus-
tified to consider METTL21B as an alternative candi-
date gene in CD4+ Tcells.
A similar case for both CD83 and SYNGR1 in B
lymphocytes might also be made. CD83 encodes a trans-
membrane member of the immunoglobulin superfamily
expressed widely on dendritic cells, but also on activated
lymphocytes; its important role in regulating B lympho-
cyte development and effector function is only now
beginning to be understood (36). SYNGR1 is an integral
membrane protein associated with presynaptic vesicles
in neuronal cells, and its function in lymphoid cells
remains obscure. However, caution should be exercised
when interpreting transcript eQTLs in isolation (37),
and validation of our findings at the protein level should
be prioritized. This was amply illustrated by Simpfendorfer
et al, who, similar to our findings at the 8p23 locus,
highlighted BLK transcript expression as subject to an
eQTL in lymphocytes; however, the CD4+ T cell–specific
effect was not sustained at the protein level in these
cells. By measuring allelic expression imbalance, those
authors went on to demonstrate a robust eQTL for both
RNA and protein expression in naive/transitional B cell
subsets isolated from umbilical cord blood, which was less
evident in whole B cells, suggesting that disease risk is con-
ferred during early B cell development rather than by
CD4+ T cells (38), potentially via dysregulated B cell
receptor signaling (39).
Our study is the first to provide evidence of an
eQTL SNP in CD4+ lymphocytes that was in perfect
LD with the RA-associated variant at the 1p36 locus, a
variant that regulates PADI4 gene expression. The
PADI4 gene has already been recognized as a strong
causal candidate for the disease, encoding peptidyl-
arginine deiminase 4, a key enzyme involved in post-
translational citrullination of arginine residues that
yields neoepitopes against which RA-specific anti–
citrullinated peptide autoantibodies may be raised (28).
However, distinct mechanisms of CD4+ lymphocyte
dysregulation now warrant further investigation (40).
Similarly, the finding that IKZF3 is subject to
an eQTL in CD4+ lymphocytes is, to our knowledge, a
novel observation and is intriguing, given the proven role
of the transcription factor product of this gene in regulat-
ing interleukin-10 production by these cells (41).
Conceiveably, our observations with regard to
PADI4 and IKZF3 could be interpreted as evidence
that putatively common causal SNPs augment gene
expression in CD4+ T cells uniquely under the particu-
lar biologic and/or environmental circumstances of
early arthritis. However, our analysis of interactions
between specific biologic covariates and eQTL effects
did not support such an interpretation: in particular,
the IKZF rs9916765 eQTL slope gradient was unaf-
fected by markers of systemic inflammation, T cell acti-
vation, or clinical diagnosis (see Supplementary Figures
5D–F, http://onlinelibrary.wiley.com/doi/10.1002/art.40393/
abstract). While this could be seen as surprising, given
the previously reported differences between CD4+ T cell
eQTLs according to activation status in vitro (30), the
contrastingly cross-sectional nature of our study, which
focused on unstimulated ex vivo cells from systemically
inflamed and uninflamed peripheral blood samples, ren-
der the findings complimentary rather than contradictory,
in our view. Indeed, the fact that eQTL effects did not
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differ according to disease classification (e.g., RA versus
non-RA) in our early arthritis population recalls the find-
ings in a study by Peters et al, whereby inflammatory
bowel disease–specific eQTLs resided outside of known
risk loci for that condition (42). Further work is therefore
needed to elucidate the mechanisms by which eQTL
effects may wax or wane at a cellular level within the
in vivo environment.
Our data extend the understanding of the causal
candidate gene landscape in early RA, highlighting sev-
eral such candidates that now deserve further investiga-
tion in defined primary lymphocyte populations. In the
future, the possibility that eQTL effects may exhibit
heterogeneity between subsets of CD4+ T and/or B
lymphocytes should be considered, since these popula-
tions are well-known to comprise functionally diverse
compartments. Moreover, it is likely that larger integra-
tive studies, including meta-analyses of accumulating
lymphocyte eQTL data sets in relevant populations, will
be required to expand on this. Such work will have
additional value in the identification of trans-eQTL
effects, which, because of power considerations, we
were not able to address in the present study.
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